Actavis Joins the Divestment Bandwagon - Analyst Blog
20 Januar 2014 - 11:55PM
Zacks
Actavis (ACT) has received a binding offer for
its generics commercial operations in seven Western European
countries (France, Italy, Spain, Portugal, Belgium, Germany and the
Netherlands) from India-based Aurobindo Pharma Limited. Total value
of the deal is expected to be €30 million.
If the deal goes through, Aurobindo Pharma will acquire Actavis'
pharmaceutical commercial infrastructure including personnel,
commercial infrastructure, products, marketing authorizations and
dossier licenses in the covered countries. Aurobindo Pharma
estimates that the net sales of the acquired businesses will be
approximately €320 million in 2013, representing an increase of
more than 10% from the year ago period. The companies will also
enter into a supply agreement.
The divestment will allow Actavis to focus more on its core and
higher growth areas (including Central and Eastern Europe and
Southeast Asia). We are positive on the potential deal.
Industry-Wide Trend
We note that Actavis is not the only company focusing on its core
assets and divesting (or planning to divest) its non-core assets to
drive growth. Several other big pharma companies have either
divested or entered into agreements to divest their non core
assets. For example, GlaxoSmithKline (GSK)
divested several non-core brands from its Consumer Healthcare
segment and Johnson & Johnson (JNJ) recently
received a binding offer for its Ortho-Clinical Diagnostics (OCD)
business.
In the near term, we believe that investor focus will remain on
Actavis’ release of fourth quarter and full year 2013 results (Feb
20). Actavis expects fourth quarter 2013 adjusted earnings to be
slightly above the high end of the previously issued guidance of
$2.95–$3.05 per share.
The Zacks Consensus Estimate currently stands at $3.02, well
below the company’s guidance. We expect to see significant upward
revisions in earnings estimates for the fourth quarter and full
year 2013.
Actavis carries a Zacks Rank #1 (Strong Buy). Other stocks which
look attractive at current levels include Actelion
Ltd. (ALIOF). The stock carries the same Zacks Rank as
Actavis.
ACTAVIS PLC (ACT): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
(USOTC:ALIOF)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über (OTCMarkets): 0 Nachrichtenartikel
Weitere Actelion Ltd. (PC) News-Artikel